AGENTS PRODUCED FROM CBP501 AND METHODS ON THEIR BASIS FOR INHIBITING G2 CELL STOP AND SENSITIZING CELLS TO DNA-DAMAGING AGENTS

摘要

1. The acetate salt of the peptide compound represented by the sequence: (d-Bpa) (d-Ser) (d-Trp) (d-Ser) (d-Phe-2,3,4,5,6-F) (d- Cha) (d-Arg) (d-Arg) (d-Arg) (d-Gln) (d-Arg) (d-Arg) (SEQ ID NO: 1). ! 2. An agent for the prevention or treatment of cell proliferative disorders, containing the acetate salt of the peptide compound according to claim 1 as an active ingredient. ! 3. The agent according to claim 2, where the cell proliferative disorder is at least one cell proliferative disorder selected from the group consisting of breast cancer, prostate cancer, pancreatic cancer, gastric cancer, lung cancer, pleural mesothelioma, colon cancer, rectal cancer, colon cancer, small intestine cancer, esophageal cancer, duodenal cancer, lingual cancer, pharyngeal cancer, salivary gland cancer, brain cancer, schwannoma, liver cancer, kidney cancer, cancer of the gall ducts, endometrial cancer, cervical cancer, uterine cancer, ovarian cancer, bladder cancer, urethra cancer, skin cancer, angioma, malignant lymphoma, malignant melanoma, thyroid cancer, parathyroid cancer, nasal cancer, paranasal cancer, hearing cancer, cancer of the bottom of the oral cavity, cancer of the larynx, unknown primary cancer, cancer of the parotid gland, submandibular cancer, bone tumor, angiofibroma, retinal sarcoma, cancer of the penis, testicular tumor, pediatric idnogo cancer, Kaposi's sarcoma, Kaposi's sarcoma derived from AIDS, maxillary tumor (maxillary) sinus, fibrous histiocytoma, leiomyosarcoma, rhabdomyosarcoma, multiple myeloma and leukemia. ! 4. The agent according to claim 2, where the cell pro